Masaya Okada

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

Jun Imagawa, Hideo Tanaka, Masaya Okada et al. · The Lancet Haematology · 2015 · 297 citations

Hematological Malignancy, Medicine, Chronic Myeloid Leukaemia +11

Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study

Kazuo Muroi, Koichi Miyamura, Masaya Okada et al. · International Journal of Hematology · 2015 · 156 citations

Regenerative Medicine, Cell Therapy, Marrow Transplantation +11

Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment

Masaya Okada, Jun Imagawa, Hideo Tanaka et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 116 citations · Full text

Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial

Shinya Kimura, Jun Imagawa, Kazunori Murai et al. · The Lancet Haematology · 2020 · 100 citations

Hematological Malignancy, Medicine, First-line Dadi Trial +9

Predicting the severity of graft-versus-host disease from interleukin-10 levels after bone marrow transplantation

Hiroyuki Takatsuka, Y Takemoto, Takahiro Okamoto et al. · Bone Marrow Transplantation · 1999 · 53 citations

Graft-versus-host Disease, Transplantation, Marrow Transplantation +12